Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21

Podobne zapisy

• Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
  od: Annels, Nicola E., i wsp.
  Wydane: (2018)
• Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
  od: Pandha, Hardev, i wsp.
  Wydane: (2015)
• Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
  od: Annels, Nicola E., i wsp.
  Wydane: (2020)
• Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
  od: Simpson, G R, i wsp.
  Wydane: (2012)
• Oncolytic Viruses: Time to Compare, Contrast, and Combine?: 5th International Meeting on Replicating Oncolytic Virus Therapeutics Banff, Alberta, Canada, 18–22 March 2009
  od: Pandha, Hardev, i wsp.
  Wydane: (2009)